Kintara Therapeutics Financials

Based on the key indicators related to Kintara Therapeutics' liquidity, profitability, solvency, and operating efficiency, Kintara Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.
With this module, you can analyze Kintara financials for your investing period. You should be able to track the changes in Kintara Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Kintara Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kintara Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Kintara Therapeutics' assets may result in an increase in income on the income statement.
Evaluating Kintara Therapeutics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Kintara Therapeutics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Kintara Therapeutics' relative financial performance

Chance Of Distress

Over 100

 
100  
 
Zero
Dangerous
Kintara Therapeutics has more than 100 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Kintara Therapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Kintara Therapeutics' odds of distress score SHOULD NOT be confused with the real chance of Kintara Therapeutics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Kintara is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Kintara Therapeutics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Kintara Therapeutics' official financial statements usually reflect Kintara Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kintara Therapeutics. For example, before you start analyzing numbers published by Kintara accountants, it's critical to develop an understanding of what Kintara Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kintara Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kintara Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kintara Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kintara Therapeutics. Please utilize our Beneish M Score to check the likelihood of Kintara Therapeutics' management manipulating its earnings.

Kintara Therapeutics Company Summary

Kintara Therapeutics competes with US Silica, MYR, SFL, Newpark Resources, and Hurco Companies. DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California. DelMar Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS49720K1016
Business Address12707 High Bluff
SectorHealthcare
IndustryBiotechnology
BenchmarkNYSE Composite
Websitewww.delmarpharma.com
Phone858 350 4364
CurrencyUSD - US Dollar
You should never invest in Kintara Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Kintara Stock, because this is throwing your money away. Analyzing the key information contained in Kintara Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Kintara Therapeutics Key Financial Ratios

Generally speaking, Kintara Therapeutics' financial ratios allow both analysts and investors to convert raw data from Kintara Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Kintara Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Kintara Therapeutics reports annually and quarterly.

Kintara Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kintara Therapeutics's current stock value. Our valuation model uses many indicators to compare Kintara Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kintara Therapeutics competition to find correlations between indicators driving Kintara Therapeutics's intrinsic value. More Info.
Kintara Therapeutics is one of the top stocks in cash per share category among related companies. It is one of the top stocks in net income category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kintara Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kintara Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kintara Therapeutics' earnings, one of the primary drivers of an investment's value.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Kintara Stock

If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world